Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical School, shared a post by Raffaele Colombo, Director of Medicinal Chemistry at Zymeworks Inc. on X, adding:
”One more ADC to treat cancer just approved.”
Quoting Raffaele Colombo‘s post:
”FDA approves pivekimab sunirine [PVEK, IMGN632] based on CADENZA trial!
CD123‐targeting antibody with DGN549 payload.
15th ADC approved by FDA
20th ADC worldwide
1st CD123 ADC
1st IGN payload (similar to PBD).”
Other Articles Featuring Paolo Tarantino and Raffaele Colombo On OncoDaily.